Rosa Amorim-Figueiredo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rosa Amorim-Figueiredo has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Ana Pereira Lemos
Infectious Diseases Unit, Pediatric Department, Hospital Dona Estefânia, Unidade Local de Saúde São José, Academic Clinical Centre of Lisbon, Lisbon, Portugal
1 shared publication - Beatriz Costa1 shared publication
- Carla Conceição
Neuroradiology Unit. Hospital Dona Estefânia. Unidade Local de Saúde São José. Lisbon
1 shared publication - Carla Mendonça
Centro de Neuropediatria e Desenvolvimento, Centro Hospitalar Universitário do Algarve, Faro 8000, Portugal
1 shared publication - Fátima F. Pinto
Universidade NOVA de Lisboa, Serviço de Cardiologia Pediátrica, Centro de Referência de Cardiopatias Congénitas, CHULC, EPE - Hospital de Santa Marta, Portugal
1 shared publication Inês Madureira
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by S. Karger AG in Case Reports in Neurology
- Vol. 18 (1) , 347-355
Chorea as a Non-Thrombotic Manifestation in an Adolescent with Systemic Lupus Erythematosus, Antiphospholipid Syndrome and Heterozygous Prothrombin G20210A Gene Mutation: A Case Report
Introduction: Chorea is a rare movement disorder in the context of systemic lupus erythematosus (SLE). Although basal ganglia thrombosis, autoimmune injury or neuronal direct lesion have been proposed as possible explanations, its mechanism is still unknown. It is important to understand its pathogenesis so that the best treatments can be identified. Case Presentation: A 12-year-old female adolescent with choreoathetoid movements of the trunk and four limbs, slurred speech, hypophonia and orofacial dyskinesia with 14 days of evolution. Brain magnetic resonance imaging revealed recent subcortical ischemic lesions in both frontal and parietal lobes. Basal ganglia lesions were not found. She started acetylsalicylic acid (ASA) and tetrabenazine, with chorea improvement. Transcranial Doppler ultrasound identified a microembolic sign between the left middle cerebral and anterior cerebral arteries. Therefore, ASA was switched to enoxaparin. Antinuclear antibodies and lupus anticoagulant (LAC) antibody were positive, with heterozygous prothrombin G20210A gene mutation being found. Five-day methylprednisolone pulses 1 g/day were performed, followed by prednisolone 60 mg/day. Intravenous immunoglobulin was administered, and hydroxychloroquine was initiated. Due to progressive microscopic hematuria and non-nephrotic proteinuria, a kidney biopsy was performed, being compatible with class V lupus nephritis. Consequently, mycophenolate mofetil and enalapril were started. Chorea resolved 5 days later. After discharge, LAC remained positive, but no more neurologic symptoms occurred. Conclusions: Basal ganglia thrombosis does not seem to be the most likely mechanism of SLE-related chorea. Antiphospholipid antibodies alone do not seem to be enough to trigger chorea. Further studies are needed to clarify the mechanisms that trigger this movement disorder.
- 1 January 2026
- Published by S. Karger AG in Case Reports in Neurology
- Vol. 18 (1) , 347-355
Open AccessChorea as a Non-Thrombotic Manifestation in an Adolescent with Systemic Lupus Erythematosus, Antiphospholipid Syndrome and Heterozygous Prothrombin G20210A Gene Mutation: A Case Report
Introduction: Chorea is a rare movement disorder in the context of systemic lupus erythematosus (SLE). Although basal ganglia thrombosis, autoimmune injury or neuronal direct lesion have been proposed as possible explanations, its mechanism is still unknown. It is important to understand its pathogenesis so that the best treatments can be identified. Case Presentation: A 12-year-old female adolescent with choreoathetoid movements of the trunk and four limbs, slurred speech, hypophonia and orofacial dyskinesia with 14 days of evolution. Brain magnetic resonance imaging revealed recent subcortical ischemic lesions in both frontal and parietal lobes. Basal ganglia lesions were not found. She started acetylsalicylic acid (ASA) and tetrabenazine, with chorea improvement. Transcranial Doppler ultrasound identified a microembolic sign between the left middle cerebral and anterior cerebral arteries. Therefore, ASA was switched to enoxaparin. Antinuclear antibodies and lupus anticoagulant (LAC) antibody were positive, with heterozygous prothrombin G20210A gene mutation being found. Five-day methylprednisolone pulses 1 g/day were performed, followed by prednisolone 60 mg/day. Intravenous immunoglobulin was administered, and hydroxychloroquine was initiated. Due to progressive microscopic hematuria and non-nephrotic proteinuria, a kidney biopsy was performed, being compatible with class V lupus nephritis. Consequently, mycophenolate mofetil and enalapril were started. Chorea resolved 5 days later. After discharge, LAC remained positive, but no more neurologic symptoms occurred. Conclusions: Basal ganglia thrombosis does not seem to be the most likely mechanism of SLE-related chorea. Antiphospholipid antibodies alone do not seem to be enough to trigger chorea. Further studies are needed to clarify the mechanisms that trigger this movement disorder.
- Open Access
- 11 June 2025
- Published by Brieflands in Innovative Journal of Pediatrics
- Vol. 35 (4)
Full Characterization of Respiratory Syncytial Virus Pediatric Admissions Before and During the COVID-19 Pandemic: A 5-Year Study
Background: It was unknown if respiratory syncytial virus (RSV) severity changed during the COVID-19 pandemic, as previous studies presented conflicting results. It is important to understand if RSV severity is affected by viral pandemics to determine the choice of the most suitable RSV prophylactic measures. Objectives: The full characterization of the pediatric RSV hospitalized population before and during the COVID-19 pandemic, searching for changes in RSV severity. Risk factors for severe RSV disease were also analyzed. Methods: A retrospective cohort study of the RSV patients admitted to a tertiary pediatric hospital between January 2017 and March 2022. The primary outcome was the need for high-flow (HF) oxygen therapy before and during the COVID-19 pandemic. Other analyzed data included age, gender, prematurity, comorbidities, reason for admission, viral coinfections, bacterial superinfection, low-flow oxygen, non-invasive and mechanical ventilation (MV), admission to the pediatric intensive care unit (PICU), and length of stay. Results: During the COVID-19 pandemic, a slight increase in severity was observed, as the need for HF increased (P = 0.001, adjusted-P = 0.008). There was also an increase in the proportion of RSV hospitalized patients aged 24 months or older (P = 0.002, adjusted-P = 0.015). There were no differences regarding the length of stay, gender, prematurity, chronic disease, reasons for admission, bacterial superinfection, viral coinfections, admission to the PICU, low-flow oxygen therapy, non-invasive ventilation (NIV), or MV. Conclusions: Our study clarified the impact of the COVID-19 pandemic on RSV severity and found an age shift in the RSV burden during the pandemic. We concluded that RSV severity may have been affected by the COVID-19 pandemic. Since RSV severity changes with viral pandemics, it is important to continue monitoring RSV epidemiology to choose the best RSV prophylactic method, such as palivizumab or nirsevimab for infants and the RSV vaccine for pregnant women, considering the birth date of the baby, RSV seasonality, and RSV severity of that season.
- 11 June 2025
- Published by Brieflands in Innovative Journal of Pediatrics
- Vol. 35 (4)
Open AccessFull Characterization of Respiratory Syncytial Virus Pediatric Admissions Before and During the COVID-19 Pandemic: A 5-Year Study
Background: It was unknown if respiratory syncytial virus (RSV) severity changed during the COVID-19 pandemic, as previous studies presented conflicting results. It is important to understand if RSV severity is affected by viral pandemics to determine the choice of the most suitable RSV prophylactic measures. Objectives: The full characterization of the pediatric RSV hospitalized population before and during the COVID-19 pandemic, searching for changes in RSV severity. Risk factors for severe RSV disease were also analyzed. Methods: A retrospective cohort study of the RSV patients admitted to a tertiary pediatric hospital between January 2017 and March 2022. The primary outcome was the need for high-flow (HF) oxygen therapy before and during the COVID-19 pandemic. Other analyzed data included age, gender, prematurity, comorbidities, reason for admission, viral coinfections, bacterial superinfection, low-flow oxygen, non-invasive and mechanical ventilation (MV), admission to the pediatric intensive care unit (PICU), and length of stay. Results: During the COVID-19 pandemic, a slight increase in severity was observed, as the need for HF increased (P = 0.001, adjusted-P = 0.008). There was also an increase in the proportion of RSV hospitalized patients aged 24 months or older (P = 0.002, adjusted-P = 0.015). There were no differences regarding the length of stay, gender, prematurity, chronic disease, reasons for admission, bacterial superinfection, viral coinfections, admission to the PICU, low-flow oxygen therapy, non-invasive ventilation (NIV), or MV. Conclusions: Our study clarified the impact of the COVID-19 pandemic on RSV severity and found an age shift in the RSV burden during the pandemic. We concluded that RSV severity may have been affected by the COVID-19 pandemic. Since RSV severity changes with viral pandemics, it is important to continue monitoring RSV epidemiology to choose the best RSV prophylactic method, such as palivizumab or nirsevimab for infants and the RSV vaccine for pregnant women, considering the birth date of the baby, RSV seasonality, and RSV severity of that season.
- Open Access
- 14 May 2024
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 11 (5) , 149
Multiresistant Kawasaki Disease in a Young Infant with Giant Aneurysms Growing Fast
Background: Kawasaki disease (KD) is a type of vasculitis in which giant coronary artery aneurysms (CAAs) can occur. There are no specific guidelines for managing giant CAAs that develop quickly and are at risk of rupture. Regarding cardiovascular drugs, only beta-blockers are formally recommended in the acute phase of KD. Case presentation: A 6-month-old male patient with multiresistant Kawasaki disease and giant CAAs that continued to enlarge after controlling systemic inflammation was examined. The patient required three doses of intravenous immunoglobulin, methylprednisolone pulses, and anakinra and infliximab to normalize systemic inflammation. Due to the rapid increment of aneurysms’ dimensions and the risk of rupture, we introduced anticoagulant therapy and propranolol plus captopril, and titration doses were introduced according to a tolerated decrease in heart rate and arterial pressure. CAAs increment stabilized and slowly reduced their dimensions. Conclusions: The authors describe an atypical case of multiresistant KD with giant rapidly increasing CAAs even after controlling systemic inflammation. The introduction of a beta-blocker and an angiotensin-converting enzyme (ACE) inhibitor was demonstrated to be useful for stabilizing giant CAAs growth and reducing the potential risk of rupture.
- 14 May 2024
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 11 (5) , 149
Open AccessMultiresistant Kawasaki Disease in a Young Infant with Giant Aneurysms Growing Fast
Background: Kawasaki disease (KD) is a type of vasculitis in which giant coronary artery aneurysms (CAAs) can occur. There are no specific guidelines for managing giant CAAs that develop quickly and are at risk of rupture. Regarding cardiovascular drugs, only beta-blockers are formally recommended in the acute phase of KD. Case presentation: A 6-month-old male patient with multiresistant Kawasaki disease and giant CAAs that continued to enlarge after controlling systemic inflammation was examined. The patient required three doses of intravenous immunoglobulin, methylprednisolone pulses, and anakinra and infliximab to normalize systemic inflammation. Due to the rapid increment of aneurysms’ dimensions and the risk of rupture, we introduced anticoagulant therapy and propranolol plus captopril, and titration doses were introduced according to a tolerated decrease in heart rate and arterial pressure. CAAs increment stabilized and slowly reduced their dimensions. Conclusions: The authors describe an atypical case of multiresistant KD with giant rapidly increasing CAAs even after controlling systemic inflammation. The introduction of a beta-blocker and an angiotensin-converting enzyme (ACE) inhibitor was demonstrated to be useful for stabilizing giant CAAs growth and reducing the potential risk of rupture.